Physician profile
Imran Mohammed
NPI 1174625396
$6,559.61
in general payments reported to CMS, 2019-2025
37 companies · $1,246 in 2025
The $1,246 reported for 2025 was more than what 81% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $618 · 2020: $369 · 2021: $719 · 2022: $1,172 · 2023: $1,172 · 2024: $1,263 · 2025: $1,246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,410 · Education: $271.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,410.10 |
| Education | $270.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,423.61 | 2021-2025 | |
| Astellas Pharma US INC | $581.26 | 2019-2025 | Ambisome |
| Allergan, INC. | $467.59 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $465.78 | 2019-2024 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Astrazeneca Pharmaceuticals Lp | $442.91 | 2019-2025 | Airsupra, Breztri, Fasenra |
| Intuitive Surgical, INC. | $417.41 | 2022-2025 | |
| Viiv Healthcare Company | $405.64 | 2023-2024 | Dovato, Cabenuva, Rukobia |
| Glaxosmithkline, LLC. | $264.55 | 2019-2025 | Nucala, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $99.08 | 2019-2023 | Zerbaxa, Dificid, Recarbrio |
| Abiomed | $98.28 | 2025 | |
| Amgen INC. | $79.55 | 2023-2025 | Tezspire |
| Baxter Healthcare | $70.36 | 2022-2024 | Hillrom - Vest System Model 105 Home Care |
| United Therapeutics Corporation | $69.53 | 2023-2025 | Tyvaso, Tyvaso, Orenitram |
| Takeda Pharmaceuticals U.S.A., INC. | $61.42 | 2021-2023 | Glassia |
| Actelion Pharmaceuticals US, INC. | $42.06 | 2019-2020 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $41.70 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.86 | 2022-2023 | |
| Philips North America LLC | $37.33 | 2020-2024 | (Ak6) Vest Therapy |
| Inari Medical, INC. | $37.17 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Mylan Specialty L.P. | $34.25 | 2021-2023 | Yupelri |
| Viatris Specialty LLC | $33.55 | 2025 | Yupelri |
| Boston Scientific Corporation | $33.26 | 2023 | Varithena Administration Pack |
| Genzyme Corporation | $29.70 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $29.03 | 2024 | Dupixent |
| Axsome Therapeutics, INC. | $25.06 | 2023 | Sunosi |
| Mallinckrodt Hospital Products INC. | $24.65 | 2021 | |
| Kaleo, INC. | $24.65 | 2019 | |
| Pulmonx Corporation | $24.38 | 2024 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Gilead Sciences, INC. | $24.37 | 2024 | |
| Verona Pharma, INC. | $21.96 | 2025 | Ohtuvayre |
| Grifols USA, LLC | $21.84 | 2022 | |
| Paratek Pharmaceuticals, INC. | $19.39 | 2022 | |
| Janssen Biotech, INC. | $19.39 | 2019 | |
| Genentech USA, INC. | $18.00 | 2019 | |
| Electromed, INC. | $17.63 | 2021 | |
| Emd Serono, INC. | $14.41 | 2023 | Serostim |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Imran Mohammed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.